<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335319">
  <stage>Registered</stage>
  <submitdate>12/11/2010</submitdate>
  <approvaldate>15/11/2010</approvaldate>
  <actrnumber>ACTRN12610000983000</actrnumber>
  <trial_identification>
    <studytitle>A pilot trial assessing the effect of fish oil on leptin and adiponectin levels in overweight/obese individuals.</studytitle>
    <scientifictitle>A pilot trial assessing the effect of marine lipids on leptin and adiponectin levels in overweight/obese individuals.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>University of Queensland Ethics - 2010001200</secondaryid>
    <secondaryid>Princess Alexandra Hosipital Ethics (Metro South Health Service District Human Research Ethics Committee) - HREC/10/QPAH/141</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <healthcondition>Cardiovascular Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment with commercially available marine lipid preparation at a dose of 4 x 1000mg capsules per day (each capsule contains 300mg EPA, 200mg DHA) for a period of 8 weeks</interventions>
    <comparator>Baseline data for participants will be utilised for control/comparative purposes</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in adiponectin levels measured via EDTA plasma ELISA  assays</outcome>
      <timepoint>T0, T4 and T8 (weeks)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes in leptin levels measured via EDTA plasma ELISA  assays</outcome>
      <timepoint>T0, T4 and T8 (weeks)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in Pathology results (ELFT, Omega 3 Indices, CRP, HbA1C)</outcome>
      <timepoint>T0, T4 and T8 (weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in anthropometric data (BMI, hip:waist ratio)</outcome>
      <timepoint>T0, T4 and T8 (weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Results from International Physical Activity Questionaire (IPAQ)</outcome>
      <timepoint>T0, T4 and T8 (weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Results from Fatigue Questionaire (FIS)</outcome>
      <timepoint>T0, T4 and T8 (weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Results from Fatigue 3 day unannounced dietary recall</outcome>
      <timepoint>T0, T4 and T8 (weeks)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Participants will have a BMI of 25 or greater and be generally healthy.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Concurrent use of other medications or investigational products;
Weight loss of more than 10% body weight within the last six months;
Active substance abuse (alcohol or drug dependency);
Breast feeding or pregnancy;
Smoking;
Allergies to fish oil supplements;
Major Health Conditions;
Concomitant use of anticoagulants or  statin medications (Pravastatin).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Participants will be recruited through the general population including advertisements placed at Princess Alexendra and Mater Hospitals. All participants will receive the same treatment.</concealment>
    <sequence>NA</sequence>
    <masking>Open (masking not used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>8/11/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>48</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Centre for Integrative Clinical and Molecular Medicine, University of Queensland</primarysponsorname>
    <primarysponsoraddress>Level 2, R-Wing
Princess Alexandra Hospital
Wooloongabba QLD 4102</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Centre for Integrative Clinical and Molecular Medicine, University of Queensland</fundingname>
      <fundingaddress>Level 2, R-Wing
Princess Alexandra Hospital
Wooloongabba QLD 4102</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Obesity is a global epidemic. It is associated with a high burden of chronic diseases such as type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD) and some cancers. Obesity and CVD progression have been associated with altered levels of biologically active proteins secreted by adipocytes, including the hormones adiponectin and leptin. 
This study aims to assess the effect of a high dose marine lipid supplement [dose: 4000mg per day for 8 weeks] on plasma adiponectin and leptin levels in overweight and obese individuals.</summary>
    <trialwebsite />
    <publication>Gray B, Vitetta L, Colquhoun D, et al. A pilot trial assessing the effects of marine lipids on leptin and adiponectin levels in overweight/obese individuals. 19th annual RBWH Health Care Symposium. Royal Brisbane and Women's Hospital, Brisbane2010:Poster Number 22-CS.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Queensland Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>23/09/2010</ethicapprovaldate>
      <hrec>2010001200</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Metro South Health Service District Human Research Ethics Committee</ethicname>
      <ethicaddress>Centres for Health Research (Contracts)
Level 2, Building 35
Princess Alexandra Hospital
Ipswich Road, Wooloongabba</ethicaddress>
      <ethicapprovaldate>22/09/2010</ethicapprovaldate>
      <hrec>HREC/10/QPAH/141</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Luis Vitetta</name>
      <address>Centre for Integrative Clinical and Molecular Medicine
University of Queensland
Level 2, R-Wing
Princess Alexandra Hospital
Wooloongabba  QLD  4102</address>
      <phone>61 7 3176 2903</phone>
      <fax>61 7 3176 6858</fax>
      <email>l.vitetta@uq.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor Luis Vitetta</name>
      <address>Centre for Integrative Clinical and Molecular Medicine
University of Queensland
Level 2, R-Wing
Princess Alexandra Hospital
Ipswich Road
Wooloongabba  QLD  4102</address>
      <phone>61 7 3176 2903</phone>
      <fax>61 7 3176 6858</fax>
      <email>l.vitetta@uq.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Belinda Gray</name>
      <address>Centre for Integrative Clinical and Molecular Medicine
University of Queensland
Level 2, R-Wing
Princess Alexandra Hospital
Ipswich Road
Wooloongabba  QLD  4102</address>
      <phone>+61 (0) 432 195 885</phone>
      <fax>61 7 3176 6858</fax>
      <email>belinda_gray@live.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>